Advanced Soft Tissue Sarcoma with Brian Van Tine, MD, PhD Case 1

Video

Advanced Soft Tissue Sarcoma with Brian Van Tine, MD, PhD

Case Scenario 1:

  • The patient is a 36 year-old Caucasian man, referred to a center of excellence after diagnosis of a high-grade undifferentiated pleomorphic sarcoma located in the retroperitoneum.
  • The tumor is large (8 cm), deeply seated, and unresectable because of its location and invasion of major vascular structures.
  • His performance status is 0.
Related Videos
Video 2 - "Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease"
Video 1 - "Patient Case: Pathology of Graft Versus Host Disease"
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content
Tigilanol Tiglate Wins FDA Orphan Drug Designation for Sarcoma

Tigilanol Tiglate Wins FDA Orphan Drug Designation for Sarcoma

February 16th 2024
Article

The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.

Read More

Advancing the Treatment of Alveolar Soft Part Sarcoma

Advancing the Treatment of Alveolar Soft Part Sarcoma

April 26th 2023
Podcast

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

Listen

Need for Systemic Therapy Remains in Sarcoma

Need for Systemic Therapy Remains in Sarcoma

November 27th 2023
Article

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

Read More

Advances and Pending Innovations in the Treatment of Sarcoma

Advances and Pending Innovations in the Treatment of Sarcoma

March 16th 2022
Podcast

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

Listen

FDA Grants ODD to 3 Ingredients of INT230-6 for Soft Tissue Sarcoma

FDA Grants ODD to 3 Ingredients of INT230-6 for Soft Tissue Sarcoma

September 7th 2023
Article

INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.

Read More

Mechanism-Driven Science Informs Novel Treatments in Soft Tissue Sarcoma

Mechanism-Driven Science Informs Novel Treatments in Soft Tissue Sarcoma

August 11th 2023
Article

Various combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.

Read More